FAQ

MGCD516

Known as: Multitargeted Kinase Inhibitor MGCD516 
An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon administration, multitargeted kinase… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2016
012320002016

Related topics

Related topics

2 relations
Receptor Tyrosine Kinase Inhibition

Broader (1)

sitravatinib

Related mentions per year

Related mentions per year

1990-2018
1990200020102020
MGCD516
Receptor Tyrosine Kinase Inhibition
sitravatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Targeting TRK family proteins in cancer.
The tropomyosin receptor kinase (TRK) family includes TRKA, TRKB, and TRKC proteins, which are encoded by NTRK1, NTRK2 and NTRK3… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 3
Is this relevant?
2017
2017
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases
Alzheimer's disease (AD) is a complex, multifactorial disease in which different neuropathological mechanisms are likely involved… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2016
2016
Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
Sarcomas are rare but highly aggressive mesenchymal tumors with a median survival of 10-18 months for metastatic disease… (More)
Is this relevant?
2016
2016
Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
A new series of 2-amino-4-oxo-6-substituted pyrrolo[2,3-d]pyrimidines, with an isosteric replacement of the side chain amide… (More)
Is this relevant?
2016
2016
Haematological cancer: Ponatinib in CML — keeping PACE with multiple mutations
generation, multitargeted tyrosinekinase inhibitor (TKI) ponatinib has improved the outcomes of patients with treatment… (More)
Is this relevant?
2014
2014
Tyrosine kinase receptors as molecular targets In pheochromocytomas and paragangliomas
Pheochromocytomas and paragangliomas are neuroendocrine tumors shown to be responsive to multitargeted tyrosine kinase inhibitor… (More)
Is this relevant?
2013
2013
Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells.
Dietary phytochemicals as adjuvants have been suggested to play important roles in enhancing chemotherapeutic potential owing to… (More)
Is this relevant?
2012
2012
Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration…
UNLABELLED One of the central unanswered questions in prostate cancer research is the significance of tyrosine kinase inhibitor… (More)
Is this relevant?
2001
2001
A Phase I and Pharmacokinetic Study of 1843 U 89 , a Noncompetitive Inhibitor of Thymidylate Synthase , in Patients with Advanced Solid Malignancies 1
This study was performed to assess the feasibility of administering 1843U89, a potent, noncompetitive inhibitor of thymidylate… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2000
2000
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
The scheduling of antifolate antitumor agents, including the new multitargeted autofolate LY231514 (MTA), with 5-fluorouracil was… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?